Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

Fellström, Bengt C.;Jardine, Alan G.;Schmieder, Roland E.;Holdaas, Hallvard;Pirson, Yves;et.al.
(2009) New England Journal of Medicine — Vol. 360, n° 14, p. 1395-1407 (2009)

Files

115271.pdf
  • Restricted Access
  • Adobe PDF
  • 448.18 KB
Request a copy

Details

Authors
  • Fellström, Bengt C.
    Author
  • Jardine, Alan G.
    Author
  • Schmieder, Roland E.
    Author
  • Holdaas, Hallvard
    Author
  • Pirson, YvesUCLouvain
    Collaborator
Show more
Abstract
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., De Lima, J. J., Lins, R., Mayer, G., McMahon, A. W., Parving, H.-H., Remuzzi, G., Samuelsson, O., Sonkodi, S., Sci, D., et al. (2009). Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine, 360(14), 1395-1407. https://doi.org/10.1056/NEJMoa0810177 (Original work published 2009)